Effect of Bone Morphogenetic Protein 4 in the Human Brain Glioma Cell Line U251

详细信息    查看全文

• 作者：Baohui Liu (1)
  Daofeng Tian (1)
  Wei Yi (1)
  Liquan Wu (1)
  Qiang Cai (1)
  Huimin Dong (1)
  Heng Shen (1)
  Baowei Ji (1)
  Long Wang (1)
  Shenqi Zhang (1)
  Dong Ruan (1)
  Qianxue Chen (1)
  
• 关键词：Bone morphogenetic protein 4 ; Mothers against decapentaplegic homolog 4 ; Target therapy ; U251 ; Adriamycin
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2010
• 出版时间：November 2010
• 年：2010
• 卷：58
• 期：2
• 页码：91-96
• 全文大小：354KB
• 参考文献：1. Kim, E. S., Khuri, F. R., & Herbst, R. S. (2001). Epidermal growth factor receptor biology (IMC-C225). / Current Opinion in Oncology, / 13, 506-13. CrossRef
  2. Luwor, R. B., Kaye, A. H., & Zhu, H. J. (2008). Transforming growth factor-beta (TGF-beta) and brain tumours. / Journal of Clinical Neuroscience, / 15, 845-55. CrossRef
  3. Wong, M. L., Kaye, A. H., & Hovens, C. M. (2007). Targeting malignant glioma survival signalling to improve clinical outcomes. / Journal of Clinical Neuroscience, / 14, 301-08. CrossRef
  4. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. / New England Journal of Medicine, / 344, 1031-037. CrossRef
  5. O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. / New England Journal of Medicine, / 348, 994-004. CrossRef
  6. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. / New England Journal of Medicine, / 344, 783-92. CrossRef
  7. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. / New England Journal of Medicine, / 353, 1659-672. CrossRef
  8. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. / New England Journal of Medicine, / 353, 1673-684. CrossRef
  9. Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., et al. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. / New England Journal of Medicine, / 354, 809-20. CrossRef
  10. Jiang, H., Shang, X., Wu, H., Gautam, S. C., Al-Holou, S., Li, C., et al. (2009). Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. / Journal of Experimental Therapeutics and Oncology, / 8, 25-3.
  11. Moore, L. M., Holmes, K. M., Smith, S. M., Wu, Y., Tchougounova, E., Uhrbom, L., et al. (2009). IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. / Proceedings of the National Academy of Science USA, / 106, 16675-6679. CrossRef
  12. Ducy, P., & Karsenty, G. (2000). The family of bone morphogenetic proteins. / Kidney International, / 57, 2207-214. CrossRef
  13. Takae, R., Matsunaga, S., Origuchi, N., Yamamoto, T., Morimoto, N., Suzuki, S., et al. (1999). Immunolocalization of bone morphogenetic protein and its receptors in degeneration of intervertebral disc. / Spine (Phila Pa 1976), / 24, 1397-401.
  14. Sakou, T. (1998). Bone morphogenetic proteins: from basic studies to clinical approaches. / Bone, 22, 591-03.
  15. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., et al. (1988). Novel regulators of bone formation: molecular clones and activities. / Science, / 242, 1528-534. CrossRef
  16. Su, D., Zhu, S., Han, X., Feng, Y., Huang, H., Ren, G., et al. (2009). BMP4-Smad signaling pathway mediates adriamycin-induced premature senescence in lung cancer cells. / Journal of Biological Chemistry, / 284, 12153-2164. CrossRef
  17. Piccirillo, S. G., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., et al. (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. / Nature, / 444, 761-65. CrossRef
  18. Kang, Y. (2006). Pro-metastasis function of TGFbeta mediated by the Smad pathway. / Journal of Cellular Biochemistry, / 98, 1380-390. CrossRef
  19. Massague, J., Blain, S. W., & Lo, R. S. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. / Cell, / 103, 295-09. CrossRef
  20. Deng, H., Ravikumar, T. S., & Yang, W. L. (2009). Overexpression of bone morphogenetic protein 4 enhances the invasiveness of Smad4-deficient human colorectal cancer cells. / Cancer Letters, / 281, 220-31. CrossRef
  21. Miyaki, M., & Kuroki, T. (2003). Role of Smad4 (DPC4) inactivation in human cancer. / Biochemical and Biophysical Research Communications, / 306, 799-04. CrossRef
  22. Arteaga, C. L., & Baselga, J. (2004). Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? / Cancer Cell, / 5, 525-31. CrossRef
  23. Newell, D. R. (2005). How to develop a successful cancer drug—molecules to medicines or targets to treatments? / European Journal of Cancer, / 41, 676-82. CrossRef
  24. Chen, Y. N., Mickley, L. A., Schwartz, A. M., Acton, E. M., Hwang, J. L., & Fojo, A. T. (1990). Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. / Journal of Biological Chemistry, / 265, 10073-0080.
  25. Kim, J. H., Lee, G. E., Kim, J. C., Lee, J. H., & Chung, I. K. (2002). A novel telomere elongation in an adriamycin-resistant stomach cancer cell line with decreased telomerase activity. / Molecules and Cells, / 13, 228-36.
  26. Gottlieb, J. A., Gutterman, J. U., McCredie, K. B., Rodriguez, V., & Frei, E., I. I. I. (1973). Chemotherapy of malignant lymphoma with adriamycin. / Cancer Research, / 33, 3024-028.
  27. Katagiri, H., Sato, K., Takahashi, M., Sugiura, H., Yamamura, S., & Iwata, H. (1997). Use of adriamycin-impregnated methylmethacrylate in the treatment of tumor metastases in the long bones. / Archives of Orthopaedic and Trauma Surgery, / 116, 329-33. CrossRef
  28. Miyazono, K. (2000). Positive and negative regulation of TGF-β signaling. / Journal of Cell Science, / 113, 1101-109.
  29. Goto, K., Kamiya, Y., Imamura, T., Miyazono, K., & Miyazawa, K. (2007). Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. / Journal of Biological Chemistry, / 282, 20603-0611. CrossRef
  
• 作者单位：Baohui Liu (1)
  Daofeng Tian (1)
  Wei Yi (1)
  Liquan Wu (1)
  Qiang Cai (1)
  Huimin Dong (1)
  Heng Shen (1)
  Baowei Ji (1)
  Long Wang (1)
  Shenqi Zhang (1)
  Dong Ruan (1)
  Qianxue Chen (1)
  
  1. Renmin Hospital, Wuhan University, 238 Jiefang Street, Wuhan, 430060, Hubei, China
  

文摘

The role of bone morphogenetic protein 4 (BMP4) in gliomas is not clear. We hypothesized that BMP4 inhibits proliferation in the brain glioma cell line U251 through a signaling pathway involving BMP4 and the mothers against decapentaplegic homolog 4 (SMAD4) protein. We exposed U251 cells to Adriamycin (1?g) for 48?h; cell proliferation (MTT assay), expression of BMP4 and SMAD4 (mRNA: qPCR; protein: Western blot) were studied. We further altered expression of BMP4 by overexpression or siRNA silencing, and documented cell responses to Adriamycin. Proliferation of U251 cells was significantly inhibited upon exposure to Adriamycin. This inhibition was associated with increased expression of BMP4. Further, proliferation of U251 cells was inhibited when BMP4 was overexpressed. BMP4 expression negatively correlated with expression of SMAD4, such that elevated levels of BMP4 were associated with decreased expression of SMAD4 and vice versa. The Adriamycin-induced inhibition of proliferation of U251 cells was attenuated when BMP4 was knocked down by siRNA. To conclude, BMP4 is associated with inhibition of proliferation of U251 cells; the effects of BMP4 involve the BMP4-Smad signaling pathway. BMP4 has a potential as a target for glioma therapy.